4-羟基5,6-=氢-6-四基-4H-噻吩并[2,3-b]噻喃一7,7-=氧化物和乙腈混合,缓慢加入浓硫酸进行反应,所得产物用氯磺酸或硫酸进行磺化,再和氯化亚砜反应转化为磺酰氯。该物质在四氢呋喃中,加入氨水,反应得到磺酰胺,经还原,即得产物,盐酸酸化可得其盐酸盐。
美国默克(Merck Co)公司开发,1995年在美国首次上市。碳酸酐酶抑制剂。用于治疗青光眼。
中文名 | 多佐胺 |
英文名 | Dorzolamide |
别名 | 蒲勒酮 多佐胺 杜塞酰胺 多佐胺杂质 多佐胺盐酸盐 多佐胺-2-6 (2R,4R)-2-乙基氨基-4-甲基-5,5-二氧代-5,7-二硫杂双环[4.3.0]壬-8,10-二烯-8-磺酰胺 (2R,4R)-2-乙基氨基-4-甲基-5,5-二氧代-5,7-二硫杂双环(4.3.0)壬-8,10-二烯-8-磺酰胺 |
英文别名 | Dorzolamide DORZOLAMIDE 4S,6S-Dorzolamide Dorzalamide hydrochloride DORZOLAMIDE(SUBJECTTOPATENTFREE) (4S,6S)-4-(ethylamino)-5,6-dihydro-6-methyl-7, 4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide (2r,4r)-2-ethylamino-4-methyl-5,5-dioxo-5,7-dithiabicyclo[4.3.0]nona-8,10-diene-8-sulfonamide (4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide (4R,6R)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide (4S,6S)-4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide 4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S,6S)- 4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S-cis)- 4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4R-cis)- 4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S-trans)- |
CAS | 120279-96-1 139066-77-6 149249-72-9 |
EINECS | 1533716-785-6 |
化学式 | C10H16N2O4S3 |
分子量 | 324.44 |
InChI | InChI=1/C10H18N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-8,10,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,7?,8-,10?/m0/s1 |
密度 | 1.53±0.1 g/cm3(Predicted) |
沸点 | 575.8±60.0 °C(Predicted) |
溶解度 | DMSO: 可溶物5mg/mL (澄清溶液,温热) |
折射率 | 1.626 |
酸度系数 | pKa 6.35 (Uncertain);8.50 (Uncertain) |
存储条件 | room temp |
外观 | 粉末 |
颜色 | white to beige |
物化性质 |
|
体外研究 | Component A, caused by an inward flux of CO2 and its subsequent hydration by CA-II, is blocked by Dorzolamide in a dose-dependent manner with an 50% inhibitory concentration IC 50 of 2.4 μM (95% confidence interval: 0.5-10.85 μM). |
体内研究 | Dorzolamide (3, 10, or 30 mg/kg/day, ip) synergized mitomycin C exhibits anti-tumor activity in EAC solid tumor models. Dorzolamide produces a dose-dependent decrease in the calculated ratio (relative value of 57.3±1, 25.5±1.8, and 24.3± 0.7 %, respectively). Animal Model: Female Swiss albino mice (EAC solid tumor). Dosage: 3, 10, or 30 mg/kg/day (synergized mitomycin C). Administration: IP, daily for 3 weeks. Result: Upregulated TXNIP and p53 while downregulated bcl-2. Effective in retarding the growth of EAC in mice. |
危险品标志 | Xi - 刺激性物品 |
风险术语 | 36/37/38 - 刺激眼睛、呼吸系统和皮肤。 |
安全术语 | 26 - 不慎与眼睛接触后,请立即用大量清水冲洗并征求医生意见。 |
WGK Germany | 3 |
RTECS | XJ9095169 |
4-羟基5,6-=氢-6-四基-4H-噻吩并[2,3-b]噻喃一7,7-=氧化物和乙腈混合,缓慢加入浓硫酸进行反应,所得产物用氯磺酸或硫酸进行磺化,再和氯化亚砜反应转化为磺酰氯。该物质在四氢呋喃中,加入氨水,反应得到磺酰胺,经还原,即得产物,盐酸酸化可得其盐酸盐。
美国默克(Merck Co)公司开发,1995年在美国首次上市。碳酸酐酶抑制剂。用于治疗青光眼。
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!